Last reviewed · How we verify
Vancomycin antimicrobial-lock solution
Vancomycin antimicrobial-lock solution works by binding to bacterial cell wall precursors and inhibiting peptidoglycan synthesis, killing susceptible bacteria when used as a lock solution in central venous catheters.
Vancomycin antimicrobial-lock solution works by binding to bacterial cell wall precursors and inhibiting peptidoglycan synthesis, killing susceptible bacteria when used as a lock solution in central venous catheters. Used for Prevention and treatment of central venous catheter-related bloodstream infections, Catheter lock therapy for hemodialysis and parenteral nutrition catheters.
At a glance
| Generic name | Vancomycin antimicrobial-lock solution |
|---|---|
| Also known as | vancomycin: vancomicina sala 500 mg vial., sodium heparin 1%, 5000 IU/5ml., sodium chloride 0,9% 10 ml vial. |
| Sponsor | Clinica Universidad de Navarra, Universidad de Navarra |
| Drug class | Glycopeptide antibiotic |
| Target | Bacterial cell wall (peptidoglycan precursors) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vancomycin is a glycopeptide antibiotic that prevents bacterial cell wall cross-linking by inhibiting transglycosidase and transpeptidase enzymes. When used as an antimicrobial-lock solution, it is instilled into the catheter lumen where it maintains high local concentrations to prevent biofilm formation and treat catheter-related bloodstream infections caused by susceptible organisms, particularly gram-positive bacteria.
Approved indications
- Prevention and treatment of central venous catheter-related bloodstream infections
- Catheter lock therapy for hemodialysis and parenteral nutrition catheters
Common side effects
- Local catheter site reactions
- Thrombophlebitis
- Catheter dysfunction
Key clinical trials
- Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat Peritonitis (PHASE4)
- Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI (PHASE3)
- Concentration of Antimicrobials in Catheter-lock Solutions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |